At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 83 enrolled
Drug / intervention
Azithromycin +1 moredrug
Likely dose
Azithromycin 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Double-blind Placebo-controlled Prevention Trial of Azithromycin in Lung Transplantation.
In Brief
A Phase 4 clinical trial evaluating Azithromycin and Placebo for Bronchiolitis Obliterans Syndrome and 3 related conditions. Completed, enrolled 83 participants across 1 site.
Detailed Summary
Preventive treatment with azithromycin reduces the prevalence fo Bronchiolitis Obliterans Syndrome after lung transplantation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiolitis Obliterans Syndrome, Graft Rejection, Lymphocytic Bronchiolitis, Respiratory Infection
CountriesBelgium
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2005
First PostedNov 2009
Primary CompletionDec 2009
TodayJul 2026
First PostedNov 9, 2009
Enrollment StartSep 1, 2005
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 16.6 years ago
Interventions
Azithromycindrug
Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
Placebodrug
Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.